636 studies on GLP-1 agonist class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Understanding how different antidiabetic medications affect liver enzymes like ALT is crucial for managing patients with Type 2 Diabetes Mellitus (T2DM), especially given the high prevalence of co-occurring non-alcoho…
This foundational Phase 1 study was critical in establishing the initial safety and pharmacokinetic profile of liraglutide, a drug that later became a cornerstone in the treatment of Type 2 Diabetes and obesity. The p…
If successful, this study could usher in a new era of precision medicine for obesity, moving beyond a 'one-size-fits-all' approach. The ability to use a simple saliva test to predict semaglutide efficacy could signifi…
Understanding patient experience, especially regarding injection site pain, is crucial for improving adherence to long-term treatments for conditions like Type 2 Diabetes and obesity. If one GLP-1 agonist consistently…
The insights gleaned from this large-scale, multi-country observational study will be invaluable for understanding the real-world effectiveness and safety profile of semaglutide for weight management. This data will h…
This study is critically important because obesity significantly impacts the health and longevity of kidney transplant recipients, increasing risks of complications and graft loss. If successful, this combined approac…
This Phase 4 pragmatic trial is crucial because it provides real-world evidence on semaglutide's long-term performance against a broad spectrum of existing Type 2 Diabetes treatments. Such data helps clinicians and pa…
This study is highly significant because it could establish Tirzepatide as more than just a powerful glucose-lowering agent, potentially offering a crucial benefit in addressing diabetes-related cognitive impairment. …
The successful completion of this Phase 1 safety and tolerability study is a pivotal step for LY3841136 and its potential role in obesity treatment. If LY3841136 proves to be safe and effective in combination with tir…
The findings from this study, once published, will be crucial for understanding the full therapeutic potential of incretin-based therapies beyond current GLP-1 receptor agonists. If the combined GIP and GLP-1 activati…
Given the significant public health burden of Cannabis Use Disorder and the scarcity of effective pharmacological interventions, a successful outcome from this trial could be transformative. Tirzepatide, a dual GLP-1 …
This case highlights a crucial, though likely rare, adverse event associated with rapid weight loss induced by semaglutide, a widely used GLP-1 receptor agonist. Clinicians prescribing semaglutide should be aware of t…
This case report carries significant clinical implications, particularly for endocrinologists and primary care providers prescribing tirzepatide to patients with complex endocrine histories. The finding underscores th…
Optimizing Survodutide's formulation is critical for its future development as a potential treatment for obesity and NASH. A formulation with improved bioavailability could lead to more effective dosing strategies, po…
Understanding Liraglutide's direct effects on inflammation could significantly broaden its therapeutic implications beyond glycemic control and weight management. If Liraglutide can effectively reduce adipose tissue i…
If liraglutide were found to be effective and safe as an add-on therapy for Type 1 Diabetes, it could represent a significant advancement in managing this complex condition. Such a finding could potentially lead to im…
Identifying predictive biomarkers for Liraglutide response could revolutionize obesity treatment by enabling personalized medicine. If successful, this research could allow clinicians to prescribe Saxenda® more effect…
Understanding how age affects Liraglutide's pharmacokinetics is crucial for optimizing treatment strategies, especially given the increasing prevalence of type 2 diabetes and obesity in the elderly population. If sign…
While this specific study did not yield results, the underlying hypothesis of combining GLP-1 agonists with increased Non-exercise Activity Thermogenesis (NEAT) remains highly relevant for optimizing Type 2 Diabetes m…
The concept behind this trial was significant: liraglutide, a GLP-1 receptor agonist, has shown potential in preserving beta-cell function and promoting their survival, which could theoretically enhance the success an…
The successful completion of enrollment for this Phase 3 trial is a crucial step towards potentially offering a highly effective new treatment option for obesity. If the results demonstrate significant weight loss and…
The successful completion of the REDEFINE 3 trial could have a profound impact on the management of cardiovascular disease, particularly in patients who may also have metabolic comorbidities. If CagriSema demonstrates…
If the anticipated results confirm strong efficacy and a favorable safety profile, CagriSema could represent a significant advancement in the pharmacological treatment of obesity. By combining two distinct yet complem…
The identification of predictive urinary biomarkers could revolutionize the management of Type 2 Diabetes by enabling truly personalized medicine. This approach could allow clinicians to select the most effective ther…
If successful, this novel approach could offer a significant advancement for patients with Type 2 Diabetes who are dependent on insulin. Reducing or eliminating the need for insulin injections would substantially impr…
Oral semaglutide represents a significant advancement in Type 2 Diabetes management, offering a convenient oral alternative to injectable GLP-1 receptor agonists. Real-world studies like this are vital because they pr…
If successful, this Phase 3 trial could introduce a new, potentially effective treatment option for Type 2 Diabetes patients who require additional glycemic control beyond oral medications. A positive outcome could le…
Obesity-related asthma represents a significant clinical challenge, often resistant to conventional treatments and associated with poorer outcomes. Semaglutide, by targeting obesity and potentially inflammation, offer…
The potential for Semaglutide to cause delayed gastric emptying presents a substantial challenge for surgical planning and patient safety, particularly concerning anesthesia risks. If successful, this study could esta…
The daily burden of carbohydrate counting remains a significant challenge for individuals with Type 1 Diabetes, even with the most advanced closed-loop systems. If weekly Semaglutide proves effective in reducing this …
This research is crucial for identifying cognitive-behavioral markers that predict successful long-term weight loss following bariatric surgery or liraglutide treatment. Understanding these markers could lead to more …
This case report highlights a critical safety concern, suggesting that clinicians should exercise extreme caution when reinitiating GLP-1 receptor agonists like semaglutide after a treatment break. The key implication…
Understanding the specific metabolic shifts induced by Semaglutide and Tirzepatide is crucial for optimizing obesity treatment strategies. If the study reveals significant, sustained improvements in energy expenditure…
As an active Phase 3 study with an estimated completion date of June 2026, specific efficacy and safety results comparing IBI362 and Semaglutide are not yet available. The study is designed to assess the non-inferiori…
The successful completion of this Phase 1/2 study marks a critical developmental milestone for IBI362 as a potential therapeutic agent for overweight and obesity. Establishing the initial safety profile and understand…
The successful outcome of this Phase III trial could represent a significant advancement in the treatment of overweight and obesity, particularly for the Chinese population, where specific therapeutic options are high…
The findings from this trial, once fully published, could significantly impact clinical guidelines for managing Type 2 Diabetes in the critical post-hospitalization period. Identifying effective non-insulin options li…
While this specific trial did not yield results, the underlying research questions remain highly relevant for Type 1 Diabetes management. Effectively addressing hypoglycemia-induced oxidative stress, inflammation, and…
This foundational Phase 1 study was critical for advancing liraglutide into subsequent clinical development stages. By establishing a preliminary safety and pharmacokinetic profile in humans, it provided the necessary…
This completed Phase 4 clinical trial represents a significant step towards optimizing care for morbidly obese patients undergoing bariatric surgery. If the results, once published, demonstrate improved preoperative h…
Prader-Willi Syndrome patients face profound challenges with hyperphagia and severe obesity, which significantly impact their health and quality of life. Liraglutide, with its established appetite-suppressive and weig…
The co-administration of Cagrilintide and Semaglutide represents a potentially significant advancement in the treatment paradigm for Type 2 diabetes. Semaglutide is a GLP-1 receptor agonist known for its glucose-lower…